FDA Approves A New Infusion Drug for Rheumatoid Arthritis

FDA Approves A New Infusion Drug for Rheumatoid Arthritis

FDA Approves A New Infusion Drug for Rheumatoid Arthritis

FDA Approves A New Infusion Drug for Rheumatoid Arthritis

NBN Infusions provides a comprehensive nursing and pharmacy program that services patients of all ages from pediatrics to geriatrics. NBN’s on-site, licensed pharmacy provides all required medications and equipment that patients will need for the duration of their home infusion therapy. Home Infusion Therapy involves the administration of medications using intravenous, subcutaneous and epidural routes. This care is administered to patients in the convenient and comfortable surroundings of their own home and allows them to take a more active role in their own health care. Home Infusion Therapy is not only more cost-effective than inpatient treatment, it eases the stress and anxiety of treatment resulting in better patient outcomes.

 

There are 1.3 million people in the United States that are currently living with Rheumatoid Arthritis, which is a chronic inflammatory condition. Symptoms include pain, stiffness and inflammation of the joints, which can sometimes lead to destruction of the joints and even disability in some cases.  Although there are medications for the treatment of RA, there is no known cure for Rheumatoid Arthritis.

 

Due to the amount of people living with this condition there is always a driving need to develop better treatments, that’s why the success of clinical trials are so exciting.  One of the clinical trials that held so much promise may be in route to providing help to so many people in need.

 

The FDA has approved a new drug, after a Phase III Study for Infusion of patients that are suffering with moderated to “severely active” rheumatoid arthritis in combination with methotrexate.  The pharmaceutical industry is hopeful and excited because SIMPONI ARIA is the only “fully-human anti-tumor necrosis factor (TNF)-Alpha infusible therapy” to show significant improvement in a variety of areas.  This medication displayed improvement in symptoms, physical function and demonstrated that it slowed the progression of structural damage to the area that had been treated.

 

The study originally involved 592 patients that had at least six swollen and tender joints and additional symptoms.  These patients were treated with SIMPONI ARIA plus methotrexate for at least three months.  The results revealed that 59% of the patients that received SIMPONI ARIA plus Methotrexate experienced significant improvement at week 14, in comparison 25% that received a placebo and Methotrexate.

 

Additionally, the patients had significantly improved symptoms at the 24-week milestone.  The treatment additionally decreased the rate of structural damage at week 24 and 52-week timeline, in patients with moderate to severe RA.  

 

If you would like to learn more about this study, you can read more about the study here.

 

Article originally posted by The Philadelphia Business Journal

 

If you are interested in speaking to a professional about IVIG in the treatment of Rheumatoid Arthritis, contact NBN Infusions or use the contact form below.

 


Enhanced by Zemanta